AADI BIOSCIENCE INC (AADI)
US00032Q1040 - Common Stock
AADI BIOSCIENCE INC
NASDAQ:AADI (4/19/2024, 7:00:00 PM)
After market: 1.84 0 (0%)1.84
+0.04 (+2.22%)
Company Profile
Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Pacific Palisades, California and currently employs 88 full-time employees. The company went IPO on 2018-06-26. The firm is focused on developing and commercializing precision therapies for genetically defined cancers to bring transformational therapies to cancer patients with rapamycin (mTOR) pathway driver alterations. Its lead drug product, FYARRO, is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is a form of sirolimus bound to albumin. Sirolimus is a potent inhibitor of the mTOR biological pathway and inhibits downstream signaling from mTOR, which can promote tumor growth. FYARRO is composed of nanoparticles of sirolimus bound to human albumin with an average size less than 100 nanometers. The company has also initiated a tumor-agnostic Phase II study (PRECISION 1) of FYARRO in patients with Tuberous Sclerosis Complex 1 and 2 (TSC1 and TSC2) alterations.
Company Info
AADI BIOSCIENCE INC
17383 Sunset Avenue, Suite A250
Pacific Palisades CALIFORNIA
P: 14244738055
CEO: Joseph Gardner
Employees: 88
Website: https://aadibio.com/
AADI News
a month ago - Aadi BioscienceAadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for...
a month ago - Aadi BioscienceAadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for...
a month ago - Aadi BioscienceAadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients...
2 months ago - Aadi BioscienceAadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients...
2 months ago - Aadi BioscienceAadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients...
2 months ago - Aadi BioscienceAadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients...
AADI Twits
Here you can normally see the latest stock twits on AADI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
